Cargando…

Comparison of Choi, RECIST and Somatostatin Receptor PET/CT Based Criteria for the Evaluation of Response and Response Prediction to PRRT

Aim: The most suitable method for assessment of response to peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NET) is still under debate. In this study we aimed to compare size (RECIST 1.1), density (Choi), Standardized Uptake Value (SUV) and a newly defined ZP combined paramete...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zwirtz, Kevin, Hardt, Juliane, Acker, Güliz, Baur, Alexander D. J., Pavel, Marianne, Huang, Kai, Brenner, Winfried, Prasad, Vikas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9227135/ https://www.ncbi.nlm.nih.gov/pubmed/35745849 http://dx.doi.org/10.3390/pharmaceutics14061278

Ejemplares similares

RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study
por: Lucidarme, Olivier, et al.
Publicado: (2019)

Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)
por: Solis-Hernandez, Mª Pilar, et al.
Publicado: (2019)

Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?
por: Luo, Yanji, et al.
Publicado: (2017)

Somatostatin receptor PET/CT in restaging of typical and atypical lung carcinoids
por: Prasad, Vikas, et al.
Publicado: (2015)

Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST
por: Goldmacher, Gregory V., et al.
Publicado: (2020)

Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602
por: Sato, Yozo, et al.
Publicado: (2013)

Response Evaluation and Survival Prediction Following PD‐1 Inhibitor in Patients With Advanced Hepatocellular Carcinoma: Comparison of the RECIST 1.1, iRECIST, and mRECIST Criteria
por: Zhou, Meng, et al.
Publicado: (2021)

In Comparison to PSA, Interim Ga-68-PSMA PET/CT Response Evaluation Based on Modified RECIST 1.1 After 2(nd) Cycle Is Better Predictor of Overall Survival of Prostate Cancer Patients Treated With (177)Lu-PSMA
por: Prasad, Vikas, et al.
Publicado: (2021)

Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST
por: Costelloe, Colleen M., et al.
Publicado: (2010)

WHO, RECIST, and immune-related response criteria: is it time to revisit pembrolizumab results?
por: Ades, Felipe, et al.
Publicado: (2015)

RECIST criteria: our experience in daily practice
por: De Luca, S, et al.
Publicado: (2015)

Treatment with somatostatin analogues and PRRT in metastatic middle ear adenoma with neuroendocrine features
por: Lima Ferreira, Joana, et al.
Publicado: (2021)

Choi criteria are superior in evaluating tumor response in patients treated with transarterial radioembolization for hepatocellular carcinoma
por: WENG, ZHIHONG, et al.
Publicado: (2013)

Comparison of the morphologic criteria (RECIST) and metabolic criteria (EORTC and PERCIST) in tumor response assessments: a pooled analysis
por: Kim, Hong Deok, et al.
Publicado: (2019)

Patterns of response in metastatic NSCLC during PD‐1 or PD‐L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria
por: Liang, Hongge, et al.
Publicado: (2020)

Imaging tumour response: beyond RECIST
por: Koh, Dow-Mu
Publicado: (2014)

Is There a Limitation of RECIST Criteria in Prediction of Pathological Response, in Head and Neck Cancers, to Postinduction Chemotherapy?
por: Patil, V., et al.
Publicado: (2013)

The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with [(177)Lu]-DOTATATE
por: Wetz, Christoph, et al.
Publicado: (2019)

The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization
por: Lee, Jae Seung, et al.
Publicado: (2020)

Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib
por: van der Veldt, A A M, et al.
Publicado: (2010)

Evaluation of response from axitinib per Response Evaluation Criteria in Solid Tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinoma
por: Karakiewicz, Pierre I, et al.
Publicado: (2016)

Gene Expression Analysis of Pak Choi in Response to Vernalization
por: Sun, Mengxia, et al.
Publicado: (2015)

Response assessment in metronomic chemotherapy: RECIST or PERCIST?
por: Agrawal, Archi, et al.
Publicado: (2014)

Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients
por: Delgado-Ureña, Mayte, et al.
Publicado: (2018)

Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival
por: Manitz, Juliane, et al.
Publicado: (2022)

The Role of Dual-Energy CT for the Assessment of Liver Metastasis Response to Treatment: Above the RECIST 1.1 Criteria
por: Reginelli, Alfonso, et al.
Publicado: (2023)

Circulating tumor DNA: Response Evaluation Criteria in Solid Tumors – can we RECIST? Focus on colorectal cancer
por: Spindler, Karen-Lise Garm, et al.
Publicado: (2023)

Response assessment in daily practice: RECIST and its modifications
por: Sohaib, Aslam
Publicado: (2014)

Imaging biomarkers for evaluating tumor response: RECIST and beyond
por: Ko, Ching-Chung, et al.
Publicado: (2021)

Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria
por: Velez, Erik M., et al.
Publicado: (2020)

RECIST rules
por: Sohaib, Aslam
Publicado: (2012)

Necrosis volume and Choi criteria predict the response to endoscopic ultrasonography-guided HybridTherm ablation of locally advanced pancreatic cancer
por: Testoni, Sabrina Gloria Giulia, et al.
Publicado: (2020)

Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review
por: Min, Seon Jeong, et al.
Publicado: (2016)

Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST
por: Kairemo, Kalevi, et al.
Publicado: (2019)

Author’s Response to “A Letter in Support of Real-World RECIST”
por: Griffith, Sandra D., et al.
Publicado: (2020)

iRECIST and atypical patterns of response to immuno-oncology drugs
por: Ramon-Patino, Jorge Luis, et al.
Publicado: (2022)

Osteoblastic flare in a patient with advanced gastric cancer after treatment with pemetrexed and oxaliplatin: implications for response assessment with RECIST criteria
por: Amoroso, Vito, et al.
Publicado: (2007)

Fully automated volumetric measurement of malignant pleural mesothelioma by deep learning AI: validation and comparison with modified RECIST response criteria
por: Kidd, Andrew C, et al.
Publicado: (2022)

Is response evaluation criteria in solid tumors (RECIST) effective in patient selection for radical resection after neoadjuvant immunotherapy with advanced NSCLC?
por: Xu, Yuan, et al.
Publicado: (2023)

A Conversation with Insung Choi
por: Bourzac, Katherine
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_bihcbufngr8h48e52dajht1b14